Drug- and patient-specific neurological risk profiles of α1-adrenergic blockers: evidence from FAERS and external validation in JADER
Therapeutic Advances in Drug Safety
Published online on April 27, 2026
Abstract
Therapeutic Advances in Drug Safety, Volume 17, January-December 2026.
Background:α1-Adrenergic blockers are widely used in older patients, yet nervous system adverse events associated with these agents are often considered nonspecific and remain insufficiently characterized at the population level.Objectives:To evaluate ...
Background:α1-Adrenergic blockers are widely used in older patients, yet nervous system adverse events associated with these agents are often considered nonspecific and remain insufficiently characterized at the population level.Objectives:To evaluate ...